{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-23-000056","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.370713+00:00","generated_at":"2026-06-09T03:21:31.181285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"QuidelOrtho Q3 revenue $744M, GAAP loss $0.19/sh, adj EPS $0.90; maintains FY guidance","bullets":["Total revenue $744.0M, down from $783.8M YoY; respiratory revenue declined 21% as anticipated.","GAAP net loss $(13)M, diluted loss per share $(0.19); adjusted diluted EPS $0.90 vs $1.85 prior year.","Non-respiratory revenue grew 2% (constant currency) driven by Labs business strength.","Adjusted EBITDA $169M with 23% margin; company paid down $52M on term loan in Q3, $175M year-to-date.","Fiscal 2023 guidance maintained: total revenue $2.88–$3.08B, adjusted EPS $4.85–$5.30."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-23-000056","json":"https://secwatch.observer/filing/0001906324-23-000056.json","markdown":"https://secwatch.observer/filing/0001906324-23-000056.md","text":"https://secwatch.observer/filing/0001906324-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/qdel-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:21:31.181285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0909b722e58f0cea519592457c132ceba8f0b2f0","claim":"QuidelOrtho Corp reported fiscal year 2023 results: revenue Total revenues (reported) $2.88 - $3.08 billion, EPS Adjusted diluted EPS $4.85 - $5.30. Guidance reaffirmed.","evidence_excerpt":"The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows: Total revenues (reported) $2.88 - $3.08 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"Total revenues (reported) $2.88 - $3.08 billion"},{"label":"EPS","value":"Adjusted diluted EPS $4.85 - $5.30"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7dff110e559eed511afc91a3467215451d4e1583","claim":"QuidelOrtho Corp reported third quarter ended October 1, 2023 results: revenue Third quarter revenue was $744 million, EPS Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90.","evidence_excerpt":"On November 1, 2023, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended October 1, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 1, 2023 to discuss such results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended October 1, 2023"},{"label":"Revenue","value":"Third quarter revenue was $744 million"},{"label":"EPS","value":"Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7dff110e559eed511afc91a3467215451d4e1583","claim":"QuidelOrtho Corp reported third quarter ended October 1, 2023 results: revenue Third quarter revenue was $744 million, EPS Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90.","evidence_excerpt":"Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632423000056/0001906324-23-000056-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended October 1, 2023"},{"label":"Revenue","value":"Third quarter revenue was $744 million"},{"label":"EPS","value":"Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}